CHMO20141220蚌埠.pptx

靶向治疗时代卵巢癌的规范化治疗;内容提纲; ;;Age, FIGO-stage, the presence of pleural fluid, WHO performance, status, histological type were not associated with OS Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival.;EORTC-55971– 生存结果;Conclusions Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed. ;What’s the role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer? SGO: 339/1137 (30%);Vergote I.. Gynecol Oncol, 119, 2010;GCIG Consensus Conference;与EORTC同期患者在MSKCC 回顾性比较: PDS vs NACT;Chi DS, et al. Gynecol Oncol 124, 2012;Chi DS, et al. Gynecol Oncol 124, 2012;Chi DS, et al. Gynecol Oncol 124, 2012;Conclusion;GOG 172: IP vs IV ;Survivals in EORTC vs MSKCC vs GOG172;MSKCC: A retrospective study of patients treated at one tertiary referral center with the results of a multi-institutional prospective randomized Phase III study GOG172 the EORTC–NCIC is the only prospective study excluding Stage IIIa and Stage IIIb diseases. Complete resection: How to select patients for primary debulking or interval debulking surgery with the aim of leaving no residual tumor at the time of surgery. ;Leuven criteria for NACT followed by IDS in stage IIIC and IV ovarian carcinoma ;Comparison of treatment invasiveness between upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.直接减瘤术对比新辅助化疗后减瘤术治疗III/IV期卵巢癌、输卵管癌及腹膜癌的治疗侵入性的III期研究: JCOG0602;晚期一线化疗治疗: 标准方案选择;McGuire New Engl J Med (1996) 334:1 Ozols, J Clin O